G1A Stock Analysis: GEA | XETRA
Specialty Industrial Machinery | XETRA, Germany | Market Cap: 10.305m EUR | 12M Return: 5.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 26.2M
EPS Trend: 10.1%
Qual. Beats: 0
Rev. Trend: 78.3%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
GEA Group Aktiengesellschaft is a German industrial machinery manufacturer headquartered in Düsseldorf that produces process equipment and components for the food, beverage, and pharmaceutical industries worldwide. The company operates through five segments: Separation & Flow Technologies; Liquid & Power Technologies; Food & Health Technologies; Farm Technologies; and Heating & Refrigeration Technologies, allowing it to serve customers across the full production value chain rather than just one niche.
Its product portfolio includes core process components such as separators, decanters, homogenizers, valves, and pumps, as well as integrated processing lines for brewing, fermentation, drying, packaging, and pharmaceutical manufacturing (including tablet presses and granulators). The dairy processing equipment business is a particularly established niche, while newer offerings extend to carbon capture systems, emission control, vegan and alternative-protein processing, and digital herd management for livestock farms.
GEAs business model combines large capital equipment sales with recurring revenue from spare parts, maintenance, and digital services, which is typical for industrial machinery vendors and tends to provide more stable cash flow than new-equipment sales alone. Founded in 1881 and originally known as mg technologies ag, the company adopted its current name in 2005.
- Service revenue expansion supports margin growth
- Pharma processing equipment orders accelerate on tablet press demand
- Dairy and food capital expenditure drives Separation segment backlog
| Net Income: 419.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -2.63 > 1.0 |
| NWC/Revenue: 4.80% < 20% (prev 3.21%; Δ 1.59% < -1%) |
| CFO/TA 0.10 > 3% & CFO 623.6m > Net Income 419.4m |
| Net Debt (107.2m) to EBITDA (879.3m): 0.12 < 3 |
| Current Ratio: 1.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (163.4m) vs 12m ago -0.40% < -2% |
| Gross Margin: 37.35% > 18% (prev 36.34%; Δ 1.01% > 0.5%) |
| Asset Turnover: 93.34% > 50% (prev 95.32%; Δ -1.98% > 0%) |
| Interest Coverage Ratio: 13.38 > 6 (EBIT TTM 647.0m / Interest Expense TTM 48.4m) |
| A: 0.04 (Total Current Assets 2.77b - Total Current Liabilities 2.50b) / Total Assets 6.10b |
| B: 0.15 (Retained Earnings 891.4m / Total Assets 6.10b) |
| C: 0.11 (EBIT TTM 647.0m / Avg Total Assets 5.90b) |
| D: 0.74 (Book Value of Equity 2.60b / Total Liabilities 3.50b) |
| Altman-Z'' = 2.28 = BBB |
| DSRI: 1.18 (Receivables 1.26b/1.06b, Revenue 5.51b/5.44b) |
| GMI: 0.97 (GM 36.34% / 37.35%) |
| AQI: 0.95 (AQ_t 0.38 / AQ_t-1 0.40) |
| SGI: 1.01 (Revenue 5.51b / 5.44b) |
| TATA: -0.03 (NI 419.4m - CFO 623.6m) / TA 6.10b) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of July 09, 2026, the stock is trading at EUR 59.65 with a total of 363,139 shares traded. Over the past week, the price has changed by -2.21%, over one month by +10.06%, over three months by -3.04% and over the past year by +5.34%.
Current recommended Stop Loss: 57.60 (which is 3.4% or 1.5 ATR below the current price).
GEA has no consensus analysts rating.
P/E Trailing = 24.7266
P/E Forward = 18.797
P/S = 1.8703
P/B = 3.9665
P/EG = 1.2865
Revenue TTM = 5.51b EUR
EBIT TTM = 647.0m EUR
EBITDA TTM = 879.3m EUR
Long Term Debt = 143k EUR (from longTermDebt, last fiscal year)
Short Term Debt = 126.3m EUR (from shortTermDebt, last quarter)
Debt = 569.0m EUR (from shortLongTermDebtTotal, last quarter) + Leases 246.4m
Net Debt = 107.2m EUR (calculated: Debt 569.0m - CCE 461.8m)
Enterprise Value = 10.4b EUR (10.3b + Debt 569.0m - CCE 461.8m)
Interest Coverage Ratio = 13.38 (Ebit TTM 647.0m / Interest Expense TTM 48.4m)
EV/FCF = 28.29x (Enterprise Value 10.4b / FCF TTM 368.0m)
FCF Yield = 3.53% (FCF TTM 368.0m / Enterprise Value 10.4b)
FCF Margin = 6.68% (FCF TTM 368.0m / Revenue TTM 5.51b)
Net Margin = 7.61% (Net Income TTM 419.4m / Revenue TTM 5.51b)
Gross Margin = 37.35% ((Revenue TTM 5.51b - Cost of Revenue TTM 3.45b) / Revenue TTM)
Gross Margin QoQ = 38.06% (prev 36.13%)
Tobins Q-Ratio = 1.71 (Enterprise Value 10.4b / Total Assets 6.10b)
Interest Expense / Debt = 8.50% (Interest Expense 48.4m / Debt 569.0m)
Taxrate = 30.96% (187.0m / 603.9m)
NOPAT = 446.7m (EBIT 647.0m * (1 - 30.96%))
Current Ratio = 1.11 (Total Current Assets 2.77b / Total Current Liabilities 2.50b)
Debt / Equity = 0.22 (Debt 569.0m / totalStockholderEquity, last quarter 2.60b)
Debt / EBITDA = 0.12 (Net Debt 107.2m / EBITDA 879.3m)
Debt / FCF = 0.29 (Net Debt 107.2m / FCF TTM 368.0m)
Total Stockholder Equity = 2.41b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.10% (Net Income 419.4m / Total Assets 6.10b)
RoE = 17.42% (Net Income TTM 419.4m / Total Stockholder Equity 2.41b)
RoCE = 26.87% (EBIT 647.0m / Capital Employed (Equity 2.41b + L.T.Debt 143k))
RoIC = 12.95% (NOPAT 446.7m / Invested Capital 3.45b)
WACC = 6.81% (E(10.3b)/V(10.9b) * Re(6.86%) + D(569.0m)/V(10.9b) * Rd(8.50%) * (1-Tc(0.31)))
Discount Rate = 6.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.41 | Cagr: -2.23%
[DCF] Terminal Value 73.10% ; FCFF base≈418.7m ; Y1≈367.2m ; Y5≈296.6m
[DCF] Fair Price = 28.59 (EV 4.76b - Net Debt 107.2m = Equity 4.65b / Shares 162.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 10.11 | EPS CAGR: 0.35% | SUE: 0.43 | # QB: 0
Revenue Correlation: 78.31 | Revenue CAGR: 0.99% | SUE: 0.12 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.82 | Chg30d=-8.65% | Revisions=+0% | Analysts=2
EPS next Quarter (2026-09-30): EPS=1.08 | Chg30d=-15.41% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=3.27 | Chg30d=+0.37% | Revisions=+29% | GrowthEPS=+19.5% | GrowthRev=+5.5%
EPS next Year (2027-12-31): EPS=3.58 | Chg30d=+0.20% | Revisions=+29% | GrowthEPS=+9.3% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: +36% (up=6, down=2)